Celcuity Inc.

NASDAQ•CELC

CEO: Mr. Brian F. Sullivan

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2017-09-20

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Contact Information

16305–36th Avenue North, Suite 100, Minneapolis, MN, 55446, United States

763-392-0767

www.celcuity.com

Market Cap

$5.42B

P/E (TTM)

-32.2

17.5

Dividend Yield

52W High

$120.32

52W Low

$7.58

52W Range

97%

Rank62Top 92.6%

1.9

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 1.9 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.92+31.43%

4-Quarter Trend

FCF

-$44.91M+117.89%

4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Strong Financing Activity Net cash provided by financing $336.1M for nine months, driven by $201.3M Notes and $91.6M Equity offerings.

R&D Spending Ramps Research and development expenses increased 52% to $107.4M for nine months, supporting ongoing Phase 3 trials.

Clinical Data Milestones Announced positive Phase 3 VIKTORIA-1 WT cohort data; VIKTORIA-2 trial currently enrolling patients.

Balance Sheet Strengthened Total assets grew to $476.0M by September 30, 2025, supported by recent debt and equity raises.

Risk Factors

Increased Operating Losses Net loss widened 68% to $126.1M for nine months, reflecting substantial R&D investment burn rate.

High G&A Growth General and administrative costs surged 156% to $15.6M for nine months, anticipating commercialization needs.

Substantial Indebtedness Level Total indebtedness reached $331.3M as of September 30, 2025, increasing leverage risk profile.

Regulatory Approval Uncertainty Business success hinges on timely FDA approval for gedatolisib; regulatory delays pose material risk.

Outlook

Final NDA Submission Expected Expect to complete final NDA submission for gedatolisib in the fourth quarter of 2025.

Continue Clinical Development Plan to increase R&D expenses for VIKTORIA-1, CELC-G-201, and VIKTORIA-2 Phase 3 trials.

Prepare for Commercial Launch Incurring sales and marketing expenses now in anticipation of potential FDA approval date for gedatolisib.

Capital Sufficiency Forecast Current cash and borrowings expected to finance operations through 2027 based on current plans.

Peer Comparison

Revenue (TTM)

SRPT

$2.20B

+15.6%

LEGN

$908.96M

+74.7%

RARE

$672.72M

+20.1%

Gross Margin (Latest Quarter)

LQDA

101.7%

+29.3pp

CLDX

100.0%

+0.0pp

ABCL

100.0%

+588.5pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
COGT	$5.95B	-7.5	-100.2%	27.0%
CELC	$5.42B	-32.2	-179.0%	67.3%
CGON	$5.30B	-30.2	-22.9%	0.9%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Mar 19, 2026

EPS:-$1.04

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data